Description
Description
Dulaglutide is a weekly long-acting GLP-1 receptor agonist developed by Eli Lilly and was approved to enter China in 2019. Dulaglutide is suitable for the blood glucose control of adult patients with type 2 diabetes, including single-drug and patients with poor blood glucose control after receiving metformin and/or sulfonylureas. By 2020, Eli Lilly Nederland BV is the only manufacturer in the Chinese Dulaglutide market.
According to CRI’s market research, after Dulaglutide entered the Chinese market, the sales increased rapidly from CNY0.61 million in 2019 to CNY 10.37million in 2020. The annual growth rate is approximately 1601.52%.
CRI analyzes that the sales of Dulaglutide will keep a growth trend from 2021 to 2025 due to price reduction. At the end of 2020, the negotiation of Dulaglutide medical insurance was successful. The price for 1.5mg/0.5ml Dulaglutide injection was adjusted from CNY420 to CNY149. With the implementation of the latest price, the sales volume of Dulaglutide will increase, which will lead revenue to grow. Besides, the huge patient population will also continue to expand the Dulaglutide market. In China, on average, one in ten adults has diabetes, and 90% of diabetics are Type 2 diabetes. A large number of patients increases the demand for Dulaglutide. Moreover, Dulaglutide is clinically more effective and safer compared to other GLP-1 products. Thus, the share of Dulaglutide expands in the GLP-1 product market, thereby increasing its sales.
Topics Covered:
-The impact of COVID-19 on China’s Dulaglutide market
– Sales value of China’s Dulaglutide 2016-2020
– Competitive landscape of China’s Dulaglutide market
– Prices of Dulaglutide in China
– Prices of Dulaglutide in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Dulaglutide market
– Prospect of China’s Dulaglutide market from 2021 to 2025
Table of Contents
Table of Contents
1 Relevant Concepts of Dulaglutide
1.1 Indications for Dulaglutide
1.2 Development of Dulaglutide in China
1.3 Governmental Approval of Dulaglutide in China
1.4 The Impact of COVID-19 on Dulaglutide sales in China
2 Sales of Dulaglutide in China, 2019-2020
2.1 Sales Value of Dulaglutide
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Dulaglutide
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Regions
2.3 Sales of Dulaglutide by Dosage Form in China, 2019-2020
2.3.1 Injection
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Dulaglutide Manufacturers in China, 2019-2020
3.1 Analysis of Market Share of Major Dulaglutide Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Eli Lilly Nederland BV
3.2.1 Enterprise Profile
3.2.2 Sales of TRULICITY (Eli Lilly’s Dulaglutide) in China
4 Prices of Dulaglutide for Different Manufacturers in China, 2020-2021
4.1 Eli Lilly Nederland BV (TRULICITY)
4.2 Others
5 Prospect of Chinese Dulaglutide drug Market, 2021-2025
5.1 Influential Factors of Chinese Dulaglutide Market Development
5.1.1 The Impact of COVID-19 on Chinese Dulaglutide Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Dulaglutide Injection Registration in China
Chart Sales Value of Dulaglutide Injection over the World
Chart Sales Value of Dulaglutide Injection in China, 2019-2020
Chart Sales Value of Dulaglutide Injection in China by Regions, 2019-2020
Chart Sales Volume of Dulaglutide Injection in China, 2019-2020
Chart Sales Volume of Dulaglutide Injection in China by Regions, 2019-2020
Chart Market Share by Sales Value of Top Dulaglutide Manufacturers in China, 2019-2020
Chart Sales Value and Volume of TRULICITY in China, 2019-2020
Chart Referential Prices of TRULICITY in China, 2020-2021
Chart Forecast on Sales Value of Dulaglutide in China, 2021-2025
Chart Forecast on Sales Volume of Dulaglutide in China, 2021-2025
